Results 161 to 170 of about 306,427 (235)

Hypertrophic obstructive cardiomyopathy [PDF]

The Journal of Thoracic and Cardiovascular Surgery, 1997
openaire   +1 more source

A case report of an S-ICD-recorded asystole due to SMART pass deactivation in a patient with non-obstructive hypertrophic cardiomyopathy. [PDF]

Eur Heart J Case Rep
Lajos M, Rother W, Hucko T, Graf K, Spencker S.   +4 more
europepmc   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]

JACC Case Rep
Sam R, Ananthaneni A, Planek MI, Kogan A, Gordon R.   +4 more
europepmc   +1 more source

Predictors of Higher Mavacamten Maintenance Dose in Obstructive Hypertrophic Cardiomyopathy. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Suppah M, Abdullah HA, Badr A, Ibrahim R, Farina J, Ayoub C, Arsanjani R, Geske J, Alsidawi S.   +8 more
europepmc   +1 more source

A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France. [PDF]

Eur Heart J Qual Care Clin Outcomes
Charron P, Zema C, Cotté FE, Juban A, Schmidt A, Krause T, Hurst M, Gonzalez J, Trochu JN.   +8 more
europepmc   +1 more source

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Card Fail Intersect
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Hypertrophic Obstructive Cardiomyopathy [PDF]

Journal of Clinical Pathology, 1971
openaire   +1 more source

Experiences, Values and Goals of People Living with Obstructive Hypertrophic Cardiomyopathy: Exploratory Patient Interviews. [PDF]

Patient Prefer Adherence
Fifer S, Pendleton A, Ingles J, Godsell J, Zhong Y, Krause T.   +5 more
europepmc   +1 more source

Septal reduction therapy in obstructive hypertrophic cardiomyopathy: contextualizing outcomes in an era of cardiac myosin inhibition. [PDF]

Eur Heart J Open
Govind A.
europepmc   +1 more source